Indications and Purposes
| 1 Indications And Usage Kepivance Is A Mucocutaneous Epithelial Human Growth Factor Indicated To Decrease The Incidence And Duration Of Severe Oral Mucositis In Patients With Hematologic Malignancies Receiving Myelotoxic Therapy In The Setting Of Autologous Hematopoietic Stem Cell Support. Kepivance Is Indicated As Supportive Care For Preparative Regimens Predicted To Result In ≥ Who Grade 3 Mucositis In The Majority Of Patients. ( 1.1 ) Limitations Of Use The Safety And Efficacy Of Kepivance Have Not Been Established In Patients With Non-Hematologic Malignancies ( 1.2 , 5.1 ) Kepivance Was Not Effective In Decreasing The Incidence Of Severe Mucositis In Patients With Hematologic Malignancies Receiving Myelotoxic Therapy In The Setting Of Allogeneic Hematopoietic Stem Cell Support. ( 1.2 , 14.3 ) Kepivance Is Not Recommended For Use With Melphalan 200 Mg/m 2 As A Conditioning Regimen ( 14.2 ). 1.1 Indications Kepivance Is Indicated To Decrease The Incidence And Duration Of Severe Oral Mucositis In Patients With Hematologic Malignancies Receiving Myelotoxic Therapy In The Setting Of Autologous Hematopoietic Stem Cell Support. Kepivance Is Indicated As Supportive Care For Preparative Regimens Predicted To Result In ≥ Who Grade 3 Mucositis In The Majority Of Patients. Kepivance Is A Mucocutaneous Epithelial Human Growth Factor Indicated To Decrease The Incidence And Duration Of Severe Oral Mucositis In Patients With Hematologic Malignancies Receiving Myelotoxic Therapy In The Setting Of Autologous Hematopoietic Stem Cell Support. Kepivance Is Indicated As Supportive Care For Preparative Regimens Predicted To Result In ≥ Who Grade 3 Mucositis In The Majority Of Patients. 1.2 Limitations Of Use The Safety And Efficacy Of Kepivance Have Not Been Established In Patients With Non-Hematologic Malignancies )]. The Safety And Efficacy Of Kepivance Have Not Been Established In Patients With Non-Hematologic Malignancies [See Warnings And Precautions ( 5.1 )]. Kepivance Was Not Effective In Decreasing The Incidence Of Severe Mucositis In Patients With Hematologic Malignancies Receiving Myelotoxic Therapy In The Setting Of Allogeneic Hematopoietic Stem Cell Support. Kepivance Was Not Effective In Decreasing The Incidence Of Severe Mucositis In Patients With Hematologic Malignancies Receiving Myelotoxic Therapy In The Setting Of Allogeneic Hematopoietic Stem Cell Support [See Clinical Studies ( 14.3 )] . Kepivance Is Not Recommended For Use With Melphalan 200 Mg/m As A Conditioning Regimen. Kepivance Is Not Recommended For Use With Melphalan 200 Mg/m 2 As A Conditioning Regimen [See Clinical Studies ( 14.2 )] . |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Palifermin |